A Single-center, Open-label, Randomized, Three-way, Crossover Trial to Evaluate the Bioavailability of Brexpiprazole (OPC-34712) Orally Disintegrating Tablets Relative to Brexpiprazole (OPC-34712) Conventional Tablets in Healthy Male Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Mar 2017
At a glance
- Drugs Brexpiprazole (Primary)
- Indications Agitation; Major depressive disorder; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Otsuka Pharmaceutical
- 19 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 18 Dec 2016 Planned End Date changed from 1 Nov 2016 to 1 May 2017.
- 18 Dec 2016 Planned primary completion date changed from 1 Nov 2016 to 1 May 2017.